Wittayanukorn S, et al. - Using the Surveillance, Epidemiology, and End Results-Medicare–linked database, a cohort study of 142,990 women (66 y and above) newly diagnosed with breast cancer from 2001 to 2009 was conducted to analyze the evidence of angiotensin-converting enzyme inhibitors (ACEIs)/β-blockers (BBs) on prevention of trastuzumab and/or anthracycline-induced cardiotoxicity. Researchers found that baseline characteristics, including age, non-Hispanic black, advanced cancer, region, comorbidity, preexisting cardiovascular conditions, lower socioeconomic status, and concomitant treatment were significantly related to an elevated risk of all-cause mortality and/or cardiotoxicity. In female breast cancer patients undergoing trastuzumab/anthracycline treatment, ACEIs/BBs demonstrated favorable impacts on preventing cardiotoxicity and improving survival.